Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.43 |
| ▸ | MEN1 | O00255 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443223 | 1.00 | KMT2A (0.43) | KMT2AMEN1ALDH1A1CTSKMAPT | |
| SCHEMBL463715 | 0.83 | MTNR1A (0.41) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| SCHEMBL407315 | 0.82 | MTNR1A (0.42) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| SCHEMBL439231 | 0.82 | MTNR1A (0.42) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| Hydrochloric Acid SCHEMBL440113 | 0.81 | MTNR1A (0.41) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| Hydrochloric Acid SCHEMBL440114 | 0.81 | MTNR1A (0.41) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| SCHEMBL443067 | 0.80 | KMT2A (0.39) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| SCHEMBL443068 | 0.80 | KMT2A (0.39) | KMT2AMEN1ALDH1A1MAPTMTNR1A | |
| SCHEMBL438515 | 0.80 | LIPG (0.47) | KMT2AALDH1A1CTSKTSHRHSD17B10 | |
| SCHEMBL441068 | 0.74 | PKM (0.37) | KMT2AMEN1CTSKNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | KMT2A 667/4885MEN1 4411/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.